演題詳細

ポスター / Poster

ポスター 9 (Poster 9) :CML:臨床1 (CML:Clinical Research 1)

print

日程
2013年10月11日(金)
時間
16:50 - 17:50
会場
ポスター会場 / Poster (ロイトン札幌 3F ロイトンホールABCD)
座長・司会
田中 英夫 (Hideo Tanaka):1
1:広島市立安佐市民病院 血液内科
 
前へ戻る

Long term efficacy and safety of imatinib in elderly patients with CML-CP

演題番号 : PS-1-66

赤木 智昭 (Tomoaki Akagi):1、山本 豊 (Yutaka Yamamoto):1、山口 公平 (Kouhei Yamaguchi):1、久保 恒明 (Koumei Kubo):1

1:Dept. of Haematol., Aomori Prefectural Central Hospital, Japan

 

Background: Imatinib is a rationally designated tyrosine kinase inhibitor (TKI). Based on the results of the phase III IRIS trial, imatinib was registered as first-line therapy in CML-CP. However, the median age reported for patients included in the IRIS trial was 50 years, with a range from 18 to 70 years. We conducted a retrospective study to evaluate the efficacy and safety of imatinib in elderly patients with CML-CP.Methods: From Apr. 2002 to Oct. 2010, 17 patients aged over 60 years were submitted to imatinib, and median age was 69.4 years (range, 60-85). Median follow-up time was 79.6months (range, 12-128). Efficacy and safety were assessed using rates of complete cytogenetic response (CCyR) at 12 months and drug-related adverse events (AEs). Results: The median initial dose of imatinib was 370 mg (range, 100-400mg). A permanent daily dose reduction was recorded in 15 patients (82.4%). The incidence of CCyR response at 12 months was 47.0%, respectively. Grade 3/4 non-hematological AEs including skin rash (5.8%), and pulmonary fibrosis (1.9%) were shown. Grade 3/4 hematological toxicities including neutropenia (17.6%), and thrombocytopenia (5.8%) were shown. Two patients developed solid tumor, 1 lung cancer and 1 prostate cancer. Conclusions: At 12 months, the rate of CCyR in elderly patients was low rate compared with the data from IRIS study, and approximately 82.4% of patients had discontinued because of adverse events. Age is a well-recognized adverse prognostic factor, the objective treatment of elderly CML may remain with TKI intolerance.

前へ戻る